当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3618
Yoshiaki Nakamura 1 , Kristiyana Kaneva 2 , Christine Lo 2 , Farahnaz Islam 2 , Seung Won Hyun 2 , Daniel Neems 2 , Jason Yamada-Hanff 2 , Terri Driessen 2 , Hala Boulos 2 , Chithra Sangli 2 , Richard Blidner 2 , Hideaki Bando 3 , Robert Tell 2 , Daisuke Kotani 4 , Kate Sasser 2 , Halla Nimeiri 2 , Eiji Oki 5 , Takayuki Yoshino 4
Affiliation  

Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3618-3618, June 2024.


中文翻译:


新型肿瘤初治微小残留病测定在已切除的 II 期和 III 期结直肠癌患者中的纵向临床表现:日本 CIRCULATE GALAXY 研究的子集分析。



《临床肿瘤学杂志》,第 42 卷,第 16 期_suppl,第 3618-3618 页,2024 年 6 月。
更新日期:2024-05-30
down
wechat
bug